Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 11, 2007 - Issue 10
Submit an article Journal homepage
207
Views
21
CrossRef citations to date
0
Altmetric
Review

Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer

Paraic A Kenny Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS977-225A, University of California, Berkeley, CA 94720, USA [email protected]
Pages 1287-1298 | Published online: 02 Oct 2007

Bibliography

  • ULLRICH A, COUSSENS L, HAYFLICK JS et al.: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 309(5967):418-425.
  • HOLBRO T, HYNES NE: ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. (2004) 44:195-217.
  • HIRSCH FR, VARELLA-GARCIA M, BUNN PA Jr et al.: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. (2003) 21(20):3798-3807.
  • FREDERICK L, WANG XY, ELEY G, JAMES CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. (2000) 60(5):1383-1387.
  • BHARGAVA R, GERALD WL, LI AR et al.: EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. (2005) 18(8):1027-1033.
  • LEE J, JANG KT, KI CS et al.: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer (2007) 109(8):1561-1569.
  • LASSUS H, SIHTO H, LEMINEN A et al.: Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J. Mol. Med. (2006) 84(8):671-681.
  • CHUNG CH, ELY K, MCGAVRAN L et al.: Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. (2006) 24(25):4170-4176.
  • DOWNWARD J: Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer (2003) 3(1):11-22.
  • BACHMAN KE, ARGANI P, SAMUELS Y et al.: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. (2004) 3(8):772-775.
  • CAMPBELL IG, RUSSELL SE, CHOONG DY et al.: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. (2004) 64(21):7678-7681.
  • SAMUELS Y, WANG Z, BARDELLI A et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 304(5670):554.
  • LI J, YEN C, LIAW D et al.: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 275(5308):1943-1947.
  • FURUKAWA T, FUJISAKI R, YOSHIDA Y et al.: Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod. Pathol. (2005) 18(8):1034-1042.
  • XU S, FURUKAWA T, KANAI N, SUNAMURA M, HORII A: Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet. (2005) 50(4):159-167.
  • NICHOLSON RI, GEE JM, HARPER ME: EGFR and cancer prognosis. Eur. J. Cancer (2001) 37(Suppl. 4):S9-S15.
  • PANICO L, D'ANTONIO A, SALVATORE G et al.: Differential immunohistochemical detection of transforming growth factor α, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int. J. Cancer (1996) 65(1):51-56.
  • RUSCH V, BASELGA J, CORDON-CARDO C et al.: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. (1993) 53(10 Suppl.):2379-2385.
  • SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. (1995) 19(3):183-232.
  • JOHNSTON JB, NAVARATNAM S, PITZ MW et al.: Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem. (2006) 13(29):3483-3492.
  • GARLICH JR, SU JD, MILLER T et al.: Preclinical efficacy, safety, pharmacokinetics and pharmacodynamics of the targeted PI3 kinase inhibitor SF1126. Clin. Cancer Res. (2005) 11(24):S9153.
  • GEOERGER B, KERR K, TANG CB et al.: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. (2001) 61(4):1527-1532.
  • FLAHERTY KT: Sorafenib in renal cell carcinoma. Clin. Cancer Res. (2007) 13(2 Part 2):S747-S752.
  • FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. (2003) 21(12):2237-2246.
  • KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290(16):2149-2158.
  • PEREZ-SOLER R, CHACHOUA A, HAMMOND LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(16):3238-3247.
  • SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353(2):123-132.
  • LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350(21):2129-2139.
  • PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
  • MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National cancer institute of Canada clinical trials group. J. Clin. Oncol. (2007) 25(15):1960-1966.
  • GEYER CE, FORSTER J, LINDQUIST D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. (2006) 355(26):2733-2743.
  • MOY B, GOSS PE: Lapatinib: current status and future directions in breast cancer. Oncologist (2006) 11(10):1047-1057.
  • BERNIER J: Cetuximab in the treatment of head and neck cancer. Expert Rev. Anticancer Ther. (2006) 6(11):1539-1552.
  • GIUSTI RM, SHASTRI KA, COHEN MH, KEEGAN P, PAZDUR R: FDA drug approval summary: panitumumab (vectibixTM). Oncologist (2007) 12(5):577-583.
  • BLACKHALL F, RANSON M, THATCHER N: Where next for gefitinib in patients with lung cancer? Lancet Oncol. (2006) 7(6):499-507.
  • BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases TNF-α from cells. Nature (1997) 385(6618):729-733.
  • MOSS ML, JIN SL, MILLA ME et al.: Cloning of a disintegrin metalloproteinase that processes precursor TNF-α. Nature (1997) 385(6618):733-736.
  • WHITE JM: ADAMs: modulators of cell-cell and cell-matrix interactions. Curr. Opin. Cell Biol. (2003) 15(5):598-606.
  • PESCHON JJ, SLACK JL, REDDY P et al.: An essential role for ectodomain shedding in mammalian development. Science (1998) 282(5392):1281-1284.
  • LUETTEKE NC, QIU TH, PEIFFER RL et al.: TGF-α deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell (1993) 73(2):263-278.
  • MANN GB, FOWLER KJ, GABRIEL A et al.: Mice with a null mutation of the TGF-α gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell (1993) 73(2):249-261.
  • JACKSON LF, QIU TH, SUNNARBORG SW et al.: Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. (2003) 22(11):2704-2716.
  • SAHIN U, WESKAMP G, KELLY K et al.: Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. (2004) 164(5):769-779.
  • STERNLICHT MD, SUNNARBORG SW, KOUROS-MEHR H et al.: Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development (2005) 132(17):3923-3933.
  • GSCHWIND A, HART S, FISCHER OM, ULLRICH A: TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. (2003) 22(10):2411-2421.
  • ZHANG Q, THOMAS SM, LUI VW et al.: Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc. Natl. Acad. Sci. USA (2006) 103(18):6901-6906.
  • SOOND SM, EVERSON B, RICHES DW, MURPHY G: ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking. J. Cell Sci. (2005) 118(Part 11):2371-2380.
  • FRANOVIC A, ROBERT I, SMITH K et al.: Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res. (2006) 66(16):8083-8090.
  • KENNY PA, BISSELL MJ: Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Invest. (2007) 117(2):337-345.
  • KENNY PA: Three-dimensional extracellular matrix culture models of EGFR signalling and drug response. Biochem. Soc. Trans. (2007) 35(Part 4):665-668.
  • KENNY PA, BISSELL MJ: Tumor reversion: correction of malignant behavior by microenvironmental cues. Int. J. Cancer (2003) 107(5):688-695.
  • LEE GY, KENNY PA, LEE EH, BISSELL MJ: Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods (2007) 4(4):359-365.
  • VAN DE VIJVER MJ, HE YD, VAN'T VEER LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. (2002) 347(25):1999-2009.
  • CAREY LA, PEROU CM, LIVASY CA et al.: Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA (2006) 295(21):2492-2502.
  • POTEMSKI P, KUSINSKA R, WATALA C et al.: Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology (2005) 69(6):478-485.
  • SORLIE T, PEROU CM, TIBSHIRANI R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA (2001) 98(19):10869-10874.
  • VAN DE RIJN M, PEROU CM, TIBSHIRANI R et al.: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. (2002) 161(6):1991-1996.
  • NIELSEN TO, HSU FD, JENSEN K et al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. (2004) 10(16):5367-5374.
  • RAKHA EA, EL-SAYED ME, GREEN AR et al.: Prognostic markers in triple-negative breast cancer. Cancer (2007) 109(1):25-32.
  • LIOTTA LA, TRYGGVASON K, GARBISA S et al.: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (1980) 284(5751):67-68.
  • VIHINEN P, KAHARI VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer (2002) 99(2):157-166.
  • DAVIES B, BROWN PD, EAST N, CRIMMIN MJ, BALKWILL FR: A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. (1993) 53(9):2087-2091.
  • LOW JA, JOHNSON MD, BONE EA, DICKSON RB: The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res. (1996) 2(7):1207-1214.
  • SLEDGE GW Jr, QULALI M, GOULET R, BONE EA, FIFE R: Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. (1995) 87(20):1546-1550.
  • WANG X, FU X, BROWN PD, CRIMMIN MJ, HOFFMAN RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. (1994) 54(17):4726-4728.
  • WATSON SA, MORRIS TM, COLLINS HM et al.: Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br. J. Cancer (1999) 81(1):19-23.
  • SANTOS O, MCDERMOTT CD, DANIELS RG, APPELT K: Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metast. (1997) 15(5):499-508.
  • LEIN M, JUNG K, LE DK et al.: Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate (2000) 43(2):77-82.
  • BERGERS G, JAVAHERIAN K, LO KM, FOLKMAN J, HANAHAN D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 284(5415):808-812.
  • RASMUSSEN HS, MCCANN PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther. (1997) 75(1):69-75.
  • ROWINSKY EK, HUMPHREY R, HAMMOND LA et al.: Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. (2000) 18(1):178-186.
  • POULAKI V: BMS-275291. Bristol-Myers Squibb. Curr. Opin Investig. Drugs (2002) 3(3):500-504.
  • COUSSENS LM, FINGLETON B, MATRISIAN LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295(5564):2387-2392.
  • ZUCKER S, CAO J, CHEN WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 19(56):6642-6650.
  • BECK G, BOTTOMLEY G, BRADSHAW D et al.: (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of TNF-α convertase. J. Pharmacol. Exp. Ther. (2002) 302(1):390-396.
  • ZHANG Y, XU J, LEVIN J et al.: Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpho linecarboxamide (TMI-1), a novel dual TNF-α-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J. Pharmacol. Exp. Ther. (2004) 309(1):348-355.
  • ZHANG Y, HEGEN M, XU J et al.: Characterization of (2R,3S)-2-({[4-(2butynyloxy)phenyl]sulfonyl}amino)-N, 3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme. Int. Immunopharmacol. (2004) 4(14):1845-1857.
  • CONWAY JG, ANDREWS RC, BEAUDET B et al.: Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases. J. Pharmacol. Exp. Ther. (2001) 298(3):900-908.
  • YAO W, ZHUO J, BURNS DM et al.: Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer. J. Med. Chem. (2007) 50(4):603-606.
  • ZHOU BB, PEYTON M, HE B et al.: Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 10(1):39-50.
  • LIU X, FRIDMAN JS, WANG Q et al.: Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol. Ther. (2006) 5(6):648-656.
  • FRIDMAN JS, CAULDER E, HANSBURY M et al.: Selective inhibition of ADAM metalloproteases as a movel approach for modulating ErbB pathways in cancer. Clin. Cancer Res. (2007) 13(6):1892-1902.
  • CHERNEY RJ, KING BW, GILMORE JL et al.: Conversion of potent MMP inhibitors into selective TACE inhibitors. Bioorg. Med. Chem. Lett. (2006) 16(4):1028-1031.
  • GOURLEY IS, O'TOOLE M, KIRSCH T, GAYLORD S, FATENEJAD S: Lack of efficacy of TMI-005 (apratastat) in patients with active RA on a background of methotrexate. Inflamm. Res. (2006) 55:S99-S100.
  • THABET MM, HUIZINGA TW: Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr. Opin. Investig. Drugs (2006) 7(11):1014-1019.
  • SCHERLE P, LIU X, LI J et al.: Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. J. Clin. Oncol. (2006) 24(18S):13021.
  • SMOLEN JS, STEINER G: Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. (2003) 2(6):473-488.
  • SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
  • CIARDIELLO F, TROIANI T, CAPUTO F et al.: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br. J. Cancer (2006) 94(11):1604-1609.
  • POLYCHRONIS A, SINNETT HD, HADJIMINAS D et al.: Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled Phase II randomised trial. Lancet Oncol. (2005) 6(6):383-391.
  • BASELGA J, ALBANELL J, RUIZ A et al.: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. (2005) 23(23):5323-5333.
  • VON MINCKWITZ G, JONAT W, FASCHING P et al.: A multicentre Phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res. Treat. (2005) 89(2):165-172.
  • FLETCHER L: MMPI demise spotlights target choice. Nat. Biotechnol. (2000) 18:1138-1139.
  • PAGE-MCCAW A, EWALD AJ, WERB Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. (2007) 8(3):221-233.
  • OVERALL CM, KLEIFELD O: Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer (2006) 6(3):227-239.
  • ENGELMAN JA, ZEJNULLAHU K, MITSUDOMI T et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 316(5827):1039-1043.
  • SERGINA NV, RAUSCH M, WANG D et al.: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 445(7126):437-441.
  • ARTEAGA CL, BASELGA J: Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell (2004) 5(6):525-531.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.